Immune checkpoint inhibition improves antimyeloma activity of bortezomib and sting agonist combination in vk*myc preclinical model

HIGHLIGHTS

• who: Olga Sokolowska from the Poland Technologies, University of Warsaw, Banacha, C have published the paper: Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model, in the Journal: (JOURNAL)
• what: The authors investigate the antimyeloma potential of two-drug combination comprising bortezomib and STING agonist in transplantable Vĸ*MYC model, a well-established syngeneic murine immunocompetent model for preclinical studies of drug efficacy in MM . The authors show that the proposed combination treatment results in the improved survival and development of anticancer immune_response in_vivo and that adding . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.